SecBot SecBot
Insider Cluster (3 insiders) ·Filed Mar 31, 2026

CYTK

CYTOKINETICS INC
BEARISH
Impact 6/10
Horizondays Processed7mo ago
Insider cluster: 3 insiders, $1.0M total
Actionable Insight ▼ Bearish

While the dollar amount is not massive relative to market cap, the fact that all three named executives sold simultaneously, especially the CEO, suggests a lack of near-term conviction. Traders should watch for potential softness in upcoming earnings or pipeline updates.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$66.61
T+0 close · Mar 31, 2026 · via day close
Latest settled
+31.00%
T+60 · $87.26
Vs SPY
+17.91%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 1 $66.61entry
  2. T+1 · 8mo ago +0.18%α +0.09% · $66.73
  3. T+5 · 7mo ago −3.03%α −6.80% · $64.59
  4. T+20 · 7mo ago −3.96%α −13.64% · $63.97
  5. T+60 · 5mo ago +31.00%α +17.91% · $87.26
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Three corporate insiders at Cytokinetics sold shares in the past week, totaling $964K in open-market dispositions. CEO Robert Blum accounted for over half the volume, selling $500K worth of stock, while two other executives sold smaller amounts. All trades occurred at prices between $65.00 and $66.63.

Key Financial Metrics

Direction
selling
Total Value
$964.0K
Insiders
3

Key Facts

  • CEO Robert Blum sold $500K in stock, representing the largest single transaction in the cluster.
  • Two other executives, EVPs, sold a combined $465K in shares over the same period.
  • Total open-market selling by insiders amounts to $964K, or approximately 0.012% of the company's $8.1B market cap.
  • All sales occurred at market prices between $65.00 and $66.63, indicating no block discount or distressed sale.
  • No open-market purchases were reported; all transactions were sales or non-cash derivative exercises.

Financial Impact

$964,000 in insider selling over 7 days

insider ownershipmarket sentiment

Risk Factors

  • Perception of insider pessimism, particularly given CEO participation.
  • Potential for negative sentiment ripple in a high-beta biotech stock despite modest dollar volume.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-CYTK-1775679566910

Track record

46 reports on CYTK

Performance horizon

6 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
  2. Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
  4. Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
  5. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
  6. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
  7. Nov 4, 202612d ago 8-K Bullish 6/10 No price data
  8. Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
  9. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
  10. Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
Showing 10 of 46

US Market Status

Market Closed · Opens Wed (10h 59m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 8, 2026